Related Experiment Video
Updated: Mar 6, 2026
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
Published on: June 26, 2020
Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016
Martin Lagging1, Rune Wejstål1,2, Gunnar Norkrans1
1a Department of Infectious Diseases , Institute of Biomedicine at Sahlgrenska Academy, University of Gothenburg , Gothenburg , Sweden.
Insights
Updated Swedish guidelines recommend interferon-free direct-acting antivirals for all chronic hepatitis C virus (HCV) patients. Treatment access is limited by cost, but expanded eligibility includes fertile women and prioritizes people who inject drugs (PWIDs) to reduce transmission.
Area of Science:
- Hepatology
- Infectious Diseases
- Public Health
Background:
- Chronic hepatitis C virus (HCV) infection requires updated treatment strategies.
- Direct-acting antiviral (DAA) therapies offer interferon-free treatment options.
- High medication costs remain a barrier to widespread HCV treatment.
Purpose of the Study:
- To update Swedish recommendations for HCV treatment.
- To address treatment accessibility and prioritization.
- To discuss specific patient groups and resistance factors.
Main Methods:
- Expert meeting convened to review and update treatment guidelines.
- Discussion included expanded patient eligibility criteria.
- Analysis of treatment implications for specific populations and genetic variants.
Main Results:
- Interferon-free DAA combination therapy is indicated for all chronic HCV patients.
- Prioritization for treatment now includes fertile women and people who inject drugs (PWIDs).
- Clinical significance of baseline NS5A resistance-associated variants (RAVs) for specific HCV genotypes is discussed.
Conclusions:
- Updated guidelines advocate for broad DAA treatment for HCV.
- Addressing cost and prioritizing key populations are crucial for effective HCV elimination.
- Understanding resistance profiles is important for optimizing treatment outcomes.
Abstract:
In a recent expert meeting, Swedish recommendations for the treatment of hepatitis C virus (HCV) infection were updated. An interferon-free combination of direct-acting antiviral agents is considered and indicated for all patients with chronic HCV infection, but the ability to treat all is limited primarily by high cost of medication. The group of patients prioritized for therapeutic intervention has been extended to also include fertile women desiring to become pregnant. A more thorough discussion of treatment for people who inject drugs (PWIDs) in order to diminish transmission is included, and the clinical significance of baseline NS5A resistance associated variants (RAVs), also known as resistance associated substitutions (RASs), for the treatment of HCV genotype 1a or 3 infection is discussed.
Related Concept Videos
01:26Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:28Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test